key: cord-0752184-ukde17p8
authors: Boehme, K. W.; Kennedy, J. L.; Snowden, J.; Owens, S. M.; Kouassi, M.; Mann, R. L.; Paredes, A.; Putt, C.; James, L.; Jin, J.; Du, R.; Kirkpatrick, C. R.; Modi, Z.; Caid, K.; Zohoori, N.; Kothari, A.; Boyanton, B.; Forrest, J. C.
title: Estimated pediatric SARS-CoV-2 seroprevalence in Arkansas over the first year of the COVID-19 pandemic
date: 2021-08-05
journal: nan
DOI: 10.1101/2021.08.04.21261592
sha: f49322217060627e6f1da1e15e33f19e28cc20b5
doc_id: 752184
cord_uid: ukde17p8

ABSTRACT Importance: As vaccines for children under the age of 12 are not yet approved, determining the SARS-CoV-2 infection rate in children is important for decisions about protective measures to be taken during the 2021-2022 school year. Objective: To estimate the prevalence of SARS-CoV-2 antibodies in residual serum samples from pediatric patients in the state of Arkansas over the first year of the COVID-19 pandemic as an indicator of SARS-CoV-2 infection rates in children. Design: The study is a survey of SARS-CoV-2 seropositivity in children in Arkansas over the first year of the COVID-19 pandemic. From April 2020 through April 2021, remnant serum samples were collected across five time periods (waves): April 2-May 6, June 6-August 10, September 8-October 17, November 7-December 17, 2020 and April 5-April 28, 2021. Setting: The multi-site survey collected remnant serum samples from four clinics across the state of Arkansas: Arkansas Children's Hospital (ACH, Little Rock, AR), Arkansas Children's Northwest (Springdale, AR), and UAMS Family Medical Centers (Ft. Smith, AR and Pine Bluff, AR) Participants: The study population consisted of 2400 convenience serum samples from children ages 1-18 who visited hospitals or regional clinics in Arkansas for non-COVID-19-related reasons. Exposures: Infection with SARS-CoV-2. Main outcomes and measures: The presence of IgM and/or IgG antibodies to the SARS-CoV-2 Spike and Nucleoprotein were determined using a two-step enzyme-linked immunosorbent assay. Seroprevalence was estimated by demographic group, including age (1-4, 5-9, 10-14, and 15-18 years), sex, race/ethnicity (white, black, Hispanic), metropolitan status, SARS-CoV-2 PCR testing, and co-morbidities (respiratory virus infection within 6 months, asthma, hypertension, obesity, diabetes, autoimmune disease). Association with SARS-CoV-2 antibody reactivity was determined by demographic group. Results: The overall SARS-CoV-2 seroprevalence rose from 7.9% in Wave 1 (95%CI, 4.9-10.9%) to 25.8% in Wave 5 (95% CI, 22.2-29.3%), as did the age- and sex-standardized seroprevalence rate which ranged from 8.6% in Wave 1 (95%CI, 5.1-11.1%) to 24.2% in Wave 5 (95% CI, 20.1-28.2%). Hispanic children had a significantly higher risk of testing positive for SARS-CoV-2 antibodies than non-Hispanic white children in Wave 3 (RR 2.82, 95% CI, 1.81-4.38), Wave 4 (RR 1.76, 95% CI, 1.03-3.00), and Wave 5 (RR 2.37, 95% CI, 1.69-3.33) Similarly, black children also showed a significantly higher risk of testing positive for SARS-CoV-2 antibodies than white children in Wave 3 (RR 1.71, 95% CI, 1.03-2.84) and Wave 5 (RR 1.59, 95% CI, 1.08-2.34). Conclusions and relevance: The percentage of Arkansas children with SARS-CoV-2-specific antibodies increased from April 2020 to April 2021. These data indicate that many more children have been infected with SARS-CoV-2 than indicated by diagnostic testing. With the emergence of SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these results highlight the importance of including children in SARS-CoV-2 public health, clinical care, and research strategies. These findings are important for state and local officials as they consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021-2022 school year.

4 consider measures to limit SARS-CoV-2 spread in schools and daycares for the 2021-2022 98 school year. 99 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 INTRODUCTION 100

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 101 purified as described. 18 Nucleoprotein (N) was isolated as described above under denaturing 152 conditions. 19 Protein concentration was measured by DC Protein Assay (BioRad). Purified 153 proteins were confirmed by Coomassie and western blot using antigen-specific antibodies and 154 stored at −80°C. 155

ELISAs. Serum was inactivated at 56˚C for 1 h and initially screened by ELISA specific 156 for the receptor-binding domain (RBD) of the SARS-CoV-2 S protein. [20] [21] [22] [23] [24] [25] [26] Commercial anti-RBD 157 (Sino Biologicals; 1:2500 dilution) and SARS-CoV-2-RT-PCR-positive patient sera (1:50 158 dilution) served as positive controls. Purified human IgG (Sigma; 1:2500 dilution) and pre-159 COVID-19 patient sera (1:50 dilution) served as negative controls. Serum IgM and IgG were 160 detected using horse-radish peroxidase-conjugated anti-human IgM+IgG (Jackson 161

ImmunoResearch; diluted 1:5000 in PBS-T + 1% milk) and SureBlue TMB 1-Component 162 Peroxidase Substrate (SeraCare; 75 µL). After 5 min, the reaction was terminated using TMB 163 Stop Solution (SeraCare; 75 µL). The OD 450 was measured using a FluoStar Omega plate 164 reader (BMG Labtech). The final OD 450 was calculated by subtracting the mean OD 450 of blank 165 wells from the mean OD 450 of duplicate samples. The statistical cutoff for RBD binding was 166 defined as the mean OD 450 + 3 standard deviations of pre-COVID-19 sera. 26 167 Confirmation RBD-positive specimens was performed using a Four-Antigen Confirmation 168 Test (FACT) ELISA. An additional 5% of negative sera were randomly selected and tested in 169 parallel. Plates were coated with 2 µg/mL RBD, spike, nucleoprotein, or bovine serum albumin 170 (BSA; Sigma Aldrich) and FACT ELISA was performed as above. Confirmed positive samples 171 were defined by (i) a mean signal for any viral antigen over 0.6 OD 450 , (ii) BSA-subtracted viral 172 antigen value >0.3 OD 450 , (iii) and at least two positive antigens (RBD+/Spike+, RBD+/N+, 173 Spike+/N+, or RBD+/Spike+/N+). The sensitivity and specificity of the assay were 94.6% and 174 100%, respectively, based on 37 pre-COVID-19 and 19 RT-PCR-confirmed SARS-CoV-2-175 positive sera. 176 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Statistical analyses. The descriptive analysis was conducted for the study population 177 demographics by wave. SARS-CoV-2 antibody positivity rates were reported with 95% 178 confidence intervals (CI) using exact binomial distributions. The 2019 U.S. Census Bureau 179

Arkansas state population estimates (age≤18) were used to calculate the standardized positivity 180 rates. 27 The age-and sex-standardized positivity rates were reported for each wave. Univariable 181 and multivariable analyses were performed to examine the relationship between variables and 182 the SARS-CoV-2 antibody positivity rate for each wave. Relative risk was estimated by modified 183

Poisson regressions with robust error variance as the measure to characterize association 184 effects. 28 For multivariable analyses, factors being considered were age group, sex, and 185 race/ethnicity. The statistical significance level was set at 0.05. We conducted all analyses using 186 SAS version 9.4 (SAS Institute). 187

Enrollment and demographic representation. We collected 2400 total remnant 190 pediatric serum samples across five collection periods: Wave 1, April 2-May 6, 2020 (n=316); 191

Wave 2, June 6-August 10, 2020, (n=300); Wave 3, September 8-October 17, 2020, (n=594); 192 Wave 4, November 7-December 17, 2020, (n=600); and Wave 5, April 5- April 28, 2021, 193 (n=590) (Figure 1 ). Table 1 shows the demographic characteristics for the study. The 1-4 years 194 age group had the fewest samples (n=328, 13.7%) while the 10-14 years group had the most 195 samples (n=795, 33.2%). Females represented 54.8% (n=1311), whereas males represented 196 45.2% (n=1082) of total samples analyzed. The racial/ethnic distribution of the study population 197 was 55.8% non-Hispanic white (n=1289), 22.5% non-Hispanic black (n=520), and 15. 2% 198 Hispanic (n=351) . A total of 151 specimens (6.5%) were collected from patients that did not 199 identify as white, black, or Hispanic. Most samples were collected from children living in urban 200 (n=1564, 75.3%) compared to rural areas (n=513, 24.7%). Obesity was the most common co-201 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 5, 2021. ; morbidity reported (n=337, 14.1%), followed by asthma (n=239, 10.0%), diabetes mellitus 202 (n=113, 4.7%), and hypertension (n=111, 4.6%) (Supplemental table 1). 203

Estimates of seroprevalence. Table 2 shows the SARS-CoV-2 seroprevalence rates  204 by age, sex, and race/ethnicity, and the age-and sex-standardized estimates. The antibody 205 positivity rate for Wave 1 was 7.9% (95% CI, 4.9%-10.9%), which increased in Wave 2 to 9.7% 206 (95% CI, 6.3%-13.0%) and Wave 3 to 16.2% (95% CI, 13.2%-19.1%), followed by a slight 207 decrease to 13.2% (95% CI, 10.5%-15.9%) in Wave 4. The seroprevalence rate was the highest 208 in Wave 5 at 25.8% (95% CI, 22.2%-29.3%). The overall trend was statistically significant 209 (p<0.0001 using the Cochran-Armitage trend test). When standardized to match Arkansas 210 population demographics, 27 seroprevalence rates followed a similar trend to the non-adjusted 211 rates, increasing over Waves 1, 2, and 3, with a decrease in Wave 4 and a peak of 24.2% (95% 212 CI, 22.2%-29.3%) in Wave 5. The 1-4 year-old age group had the highest seroprevalence rates 213 in Wave 1 (10.7%), Wave 2 (15.2%), and Wave 3 (19.8%), but the lowest in Wave 4 (7.2%) and 214

Wave 5 (16.0%). The 15-18 year-old group had the highest percentage of reactive specimens in 215

Wave 4 (14.8%) and 10-14 year-olds were the highest in Wave 5 (30.9%). No statistically-216 significant difference was observed between males and females. 217

Hispanics had the highest seroprevalence rate in each wave, reaching a maximum of 218 43.7% in Wave 5. White persons had a higher seroprevalence rate in Waves 1 and 2, but the 219 lowest in Waves 3, 4, and 5. Concomitantly, the antibody reactivity rate in black persons was 220 lower compared to white persons in Waves 1 and 2, but higher in Waves 3, 4, and 5. The 221 highest seroprevalence rates for white (17.9%) and black (28.2%) children was observed in 222

Wave 5. Notably, the peak seroprevalence for Hispanic children was 5.5-fold higher compared 223 to white children and 1.6-fold higher than black children. 224

There was no significant marginal association between age, sex, or metropolitan status 225 and the likelihood of testing positive for SARS-CoV-2 antibodies (Supplemental table 2) . 226

However, Hispanic and black children were more likely to test positive for antibodies than white 227 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. Arkansas had SARS-CoV-2-specific antibodies. This percentage is much higher than the total 245 number of confirmed cases, which on April 28, 2021 was 11% for the total population of 246 Arkansas (335,288 positive cases according the Arkansas Department of Health, population of 247 3,011,524 according to 2019 census data). This finding indicates that those children had been 248 infected with SARS-CoV-2 and are likely to have at least some natural immunity. Conversely, 249 our findings suggest that most children in Arkansas have not been infected with SARS-CoV-2 250 and remain susceptible to infection. Although COVID-19 has been less severe in children than 251 adults early in the pandemic, emergence of the SARS-CoV-2 delta variant in May 2021 has 252 driven up infection and hospitalization rates, including among those under 18 years of age. 11,29,30 253 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021.

Developing multisystem inflammatory syndrome in children (MIS-C), a severe inflammatory 254 disorder that results from a current or recent SARS-CoV-2 infection, is also a risk for those 255 under 18 years. 31-33 Increased SARS-CoV-2 transmission rates combined with a highly 256 susceptible pediatric population raises the possibility that SARS-CoV-2 could spread rapidly in 257 schools and daycares during the upcoming school year. More children infected with SARS-CoV-258 2 could lead to an increase in the number of severe COVID-19 and MIS-C cases, and a rise in 259 pediatric deaths. 260

The first SARS-CoV-2 infections in Arkansas were reported in March 2020 ( Figure 1 ). 34 261

Arkansas schools suspended in-person learning on March 15, 2020 and many activities where 262 children congregate during the summer were closed. We found that the seroprevalence rate in 263 children increased modestly between spring and summer, suggesting that these protective 264 measures effectively limited SARS-CoV-2 spread among children in Arkansas. The larger 265 increase in seroprevalence for September/October (Wave 3), corresponded with the start of the 266 2020-2021 school year. However, masks and social distancing measures were in place, and 267 many Arkansas students began the school year as remote learners. These actions likely 268 reduced SARS-CoV-2 spread in schools, as reported outbreaks were relatively rare. Despite a 269 dramatic increase in SARS-CoV-2 cases in Arkansas during November and December, the 270 seroprevalence rate in children dropped during Wave 4. 35 The decrease suggests that 271 preventative measures in schools were effective at limiting SARS-CoV-2 spread among children 272 during this time. However, seroprevalence increased sharply in Wave 5 to approximately 25%. 273

Waves 4 and 5 were approximately three months apart and included the winter holidays, when 274 children were outside the controlled school setting, 275 and the corresponding nationwide surge in COVID-19 cases. Our data confirm that the surge 276 also impacted the pediatric population, correlating with a large increase in the number of SARS-277

CoV-2-exposed children. 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261592 doi: medRxiv preprint It is well appreciated that underrepresented racial and ethnic groups are 279 disproportionately affected by the COVID-19 pandemic. 36 We found that Hispanic children were 280 more likely to have SARS-CoV-2 antibodies compared to white children in all waves. Similarly, 281 black children were more likely to have antibodies than white children in Wave 3 and Wave 5. 282

The increase in SARS-CoV-2 antibodies in Hispanic and black children corresponded to an 283 increase in antibody level in Hispanic and black adults during the same timeframe. Kennedy preprint) Higher antibody prevalence in Hispanic and black children may reflect 285 multiple socioeconomic factors, including income inequality, economic stability, work 286 circumstances, and housing. 37 Hispanic and black parents may be less likely to hold jobs that 287 allow them to work remotely, which increases their potential exposure to SARS-CoV-2 in the 288 workplace and limits their ability to utilize remote learning or in home childcare to decrease their 289 children's SARS-CoV-2 exposure. 38, 39 Residing with parents with a higher risk of workplace 290 SARS-CoV-2 exposure combined with increased school/daycare attendance could drive 291 infection rates in minority children. Our results underscore that the pandemic exacerbated 292 existing racial and ethnic disparities. least two weeks prior to sample collection. Thus, our data reflect the pediatric seroprevalence 301 rate in Arkansas prior to widespread vaccination efforts in children and adolescents. As 302 authorization to vaccinate children younger than 12 years will not occur until late 2021, our 303 findings indicate that most children in Arkansas remain susceptible to SARS-CoV-2 infection 304 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261592 doi: medRxiv preprint entering the 2021-2022 school year. Importantly, we found that the seroprevalence rate in 305 younger children was lower than for older children and adolescents, which strongly emphasizes 306 the ongoing risk of infection for a vulnerable part of the population that cannot yet be 307 vaccinated. This is a critical consideration for policy makers as more infectious variants emerge 308 that exhibit increased infection and likelihood of causing sever disease in younger portions of 309 the population. 310

Limitations 311

Remnant serum samples may not provide an accurate representation of the Arkansas 312 population. The strengths and limitations of convenience samples are described elsewhere. 41 313

As our study samples were collected from health clinics, our sampling method may favor 314 subjects who were more ill or more willing to seek health care. It is possible that our 315 seroprevalence rates are overestimated due to potential cross reactivity between SARS-CoV-2 316 antigens and seasonal coronaviruses. 42 Some uninfected individuals, particularly children and 317 adolescents, have antibodies that react with the SARS-CoV-2 Spike protein. 42 Further, we 318 measured a combination of IgM and IgG antibody isotypes, as opposed to testing solely for 319

IgG. 43 Although studies indicate that IgG and IgM responses to SARS-CoV-2 can develop 320 simultaneously, some individuals develop detectable IgM and IgG antibodies at different 321 times. 44,45 Consequently, we may identify individuals that developed IgM and/or IgG, whereas 322 other assays may only identify specimens with IgG. Moreover, IgM can be more non-specific 323 than IgG. 46 Together, these limitations may cause an overestimation of antibody reactivity. 324

However, inclusion of multiple SARS-CoV-2 antigens and the BSA control limit the number of 325 non-specific reactions detected in our assay. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; https://doi.org/10.1101/2021.08.04.21261592 doi: medRxiv preprint pandemic, followed by a more rapid increase to 25% by the end of April 2021. This finding is 331 notable, as it is more than twice the number of confirmed SARS-CoV-2 diagnoses in the state 332 on the final collection date. No obvious comorbidities were identified for seropositivity in 333 children. Racial and ethnic disparities exist, with Hispanic and black children being at increased 334 risk for SARS-CoV-2 infection compared to white children. We conclude that SARS-CoV-2 335 infections in children are more common than previously recognized. With the emergence of 336 SARS-CoV-2 variants, recognition of long-term effects of SARS-CoV-2 even after mild or 337 asymptomatic infections, and the lack of an authorized pediatric SARS-CoV-2 vaccine, these 338 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ;

Rabenau serology assays reveals a sars-cov-2 non-responding seronegative subpopulation. 477

EClinicalMedicine. 2020;29:100651. 478 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021.

CoV-2 antibody testing from April 2, 2020 to April 28, 2021. 496 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021.

Adjusted RR (95% CI)

Wave 1 (n = 316)

Wave 2 (n = 300)

Wave 4 (n = 600)

Collection dates April 2 -May 6, 2020

June 6 -August 10, 2020

September 8 -October 17, 2020

November 7 -December 17, 2020

April 5 -April 28, 2021 Age category 1-4 years 5-9 years 10-14 years 15-18 years 

.

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 5, 2021. 

) 19.8 (10.9-28.6) (16) 18.8 (11.4-26.1) (21) 14

Age-and sex-Standardized seroprevalence rate a

6% (95% CI, 5.1%-12.1%) 9.8% (95% CI, 6.1%-13.6%) 16.9% (95% CI, 13.3%-20.6%) 12.5% (95% CI, 9